Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc., focusing on neurodegenerative therapeutics, has delayed its NASDAQ uplisting and capital raise due to adverse market conditions, instead opting for alternative funding strategies to protect shareholder interests and continue its growth. The company is gearing up for the 2025 U.S. launch of ZUNVEYL, its Alzheimer’s treatment, with bridge funding support and is exploring non-dilutive funding to advance its commercialization without compromising shareholder value.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
